Overview
Acute myeloid leukemia (AML) with CEBPA somatic mutations is a specific type of blood cancer that affects the bone marrow, where blood cells are made. In this form of AML, changes (mutations) occur in a gene called CEBPA, but these mutations happen only in the cancer cells — they are not inherited from parents. The CEBPA gene normally helps immature blood cells grow into healthy white blood cells called granulocytes. When this gene is mutated, the bone marrow produces large numbers of abnormal, immature white blood cells (called blasts) that crowd out normal blood cells. This leads to low red blood cell counts (anemia), low platelet counts (which cause easy bleeding and bruising), and a weakened immune system due to a lack of functional white blood cells. Patients typically experience fatigue, frequent infections, unexplained fevers, easy bruising or bleeding, and sometimes bone pain. AML with CEBPA mutations — especially when both copies of the gene are affected (biallelic mutations) — is generally considered to have a more favorable prognosis compared to many other types of AML. Treatment usually involves intensive chemotherapy, and in some cases, stem cell transplantation. The World Health Organization recognizes this as a distinct subtype of AML because the CEBPA mutation status significantly influences treatment decisions and expected outcomes. It is sometimes referred to as 'AML with biallelic CEBPA mutations' when both gene copies are affected, which is the most clinically significant pattern.
Key symptoms:
Extreme tiredness and fatigueFrequent or severe infectionsUnexplained feversEasy bruisingUnusual or prolonged bleeding (nosebleeds, gum bleeding)Pale skinShortness of breathBone or joint painUnexplained weight lossLoss of appetiteTiny red spots on the skin (petechiae)Swollen gumsNight sweatsFeeling of fullness or discomfort in the abdomen due to enlarged spleen or liver
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Acute myeloid leukemia with CEBPA somatic mutations.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Acute myeloid leukemia with CEBPA somatic mutations at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Acute myeloid leukemia with CEBPA somatic mutations.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Acute myeloid leukemia with CEBPA somatic mutations.
Community
No community posts yet. Be the first to share your experience with Acute myeloid leukemia with CEBPA somatic mutations.
Start the conversation →Latest news about Acute myeloid leukemia with CEBPA somatic mutations
No recent news articles for Acute myeloid leukemia with CEBPA somatic mutations.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Are my CEBPA mutations biallelic or monoallelic, and how does this affect my prognosis?,Were any other genetic mutations found in my leukemia cells that could affect my treatment plan?,What is the recommended treatment plan, and will I need a stem cell transplant?,Should I be tested for a germline (inherited) CEBPA mutation, and does my family need genetic counseling?,What are the expected side effects of treatment, and how will they be managed?,Are there any clinical trials available that might be appropriate for my specific type of AML?,What is the plan for monitoring after I achieve remission, and what signs of relapse should I watch for?
Common questions about Acute myeloid leukemia with CEBPA somatic mutations
What is Acute myeloid leukemia with CEBPA somatic mutations?
Acute myeloid leukemia (AML) with CEBPA somatic mutations is a specific type of blood cancer that affects the bone marrow, where blood cells are made. In this form of AML, changes (mutations) occur in a gene called CEBPA, but these mutations happen only in the cancer cells — they are not inherited from parents. The CEBPA gene normally helps immature blood cells grow into healthy white blood cells called granulocytes. When this gene is mutated, the bone marrow produces large numbers of abnormal, immature white blood cells (called blasts) that crowd out normal blood cells. This leads to low red
How is Acute myeloid leukemia with CEBPA somatic mutations inherited?
Acute myeloid leukemia with CEBPA somatic mutations follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Acute myeloid leukemia with CEBPA somatic mutations typically begin?
Typical onset of Acute myeloid leukemia with CEBPA somatic mutations is adult. Age of onset can vary across affected individuals.